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Peft Ventricular Assist Device
upport Normalizes Left and Right
entricular Beta-Adrenergic Pathway Properties
tefan Klotz, MD,* Alessandro Barbone, MD,† Steven Reiken, PHD,* Jeffrey W. Holmes, PHD,‡
oshifumi Naka, MD, PHD,† Mehmet C. Oz, MD,† Andrew R. Marks, MD,*§
aniel Burkhoff, MD, PHD*
ew York, New York
OBJECTIVES We hypothesized that some aspects of left ventricular assist device (LVAD) reverse
remodeling could be independent of hemodynamic factors and would primarily depend upon
normalization of neurohormonal milieu.
BACKGROUND The relative contributions of LVAD-induced hemodynamic unloading (provided to the left
ventricle [LV]) and normalized neurohormonal milieu (provided to LV and right ventricle
[RV]) to reverse remodeling are not understood.
METHODS Structural and functional characteristics were measured from hearts of 65 medically managed
transplant patients (MED), 30 patients supported with an LVAD, and 5 nonfailing donor
hearts not suitable for transplantation.
RESULTS Compared with MED patients, diastolic pulmonary pressures trended lower (p  0.01) and
cardiac output higher (p 0.001) in LVAD patients; V30 (ex vivo ventricular volume yielding
30 mm Hg, an index of ventricular size) in LVAD patients was decreased in the LV (p 
0.05) but did not change significantly in RV. The LVAD support improved force generation
in response to beta-adrenergic stimulation in isolated LV (increase in developed force from
6.3  0.6 to 18.5  4.4 mN/m2, p  0.01) and RV (increase in developed force, from 10.9
 2.0 to 20.5  3.1 mN/m2, p  0.05) trabeculae. The LVAD patients had higher
myocardial beta-adrenergic receptor density in LV (p  0.01) and RV (p  0.01). Protein
kinase A (PKA) hyperphosphorylation of the ryanodine receptor 2 (RyR2)/calcium release
channel was significantly reduced by LVAD in both RV and LV (p  0.01).
CONCLUSIONS Improved beta-adrenergic responsiveness, normalization of the RyR2 PKA phosphorylation,
and increased beta-adrenergic receptor density in LV and RV after LVAD support suggest
a primary role of neurohormonal environment in determining reverse remodeling of the
beta-adrenergic pathway. (J Am Coll Cardiol 2005;45:668–76) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.042College of Cardiology Foundation
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Heft ventricular mechanical assist devices (LVADs) reverse
any of the molecular, cellular, extracellular, ventricular
tructural, neurohormonal, and peripheral abnormalities
haracteristic of end-stage heart failure (1–16). These phe-
omena are collectively referred to as reverse remodeling (1).
e recently showed that several aspects of reverse remod-
ling including left ventricle (LV) myocyte diameter, sarco-
lasmic reticulum Ca2-ATPase, isoform 2a (SERCA2a)
evels, and force-frequency relations of isolated superfused
rabeculae were directly related to LVAD-mediated me-
hanical unloading of the LV by showing that these changes
o not occur in the right ventricle (RV) (17). We postu-
ated, however, that some aspects of reverse remodeling
ould be independent of hemodynamic factors and would
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esearch funds of the Cardiac Physiology Laboratory, Divisions of Circulatory
hysiology and Cardiology, Columbia University, and by grants from the National
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arks), and the Whitaker Foundation (to Dr. Reiken).p
Manuscript received July 13, 2004; revised manuscript received October 4, 2004,
ccepted November 16, 2004.rimarily depend on normalization of neurohormonal mi-
ieu (17).
It has recently been shown that LVAD support restores
eta-adrenergic responsiveness and reverses receptor down-
egulation in failing human hearts (13). It was postulated
hat this effect might be due to the mechanical unloading of
he ventricle. However, beta-blockers also reverse down-
egulation of beta-adrenergic receptors, improve myocardial
eta-adrenergic responsiveness, and induce some degree of
everse remodeling without significant hemodynamic un-
oading of either ventricle and without substantial improve-
ent in systemic hemodynamics (18–25).
The RV and LV mainly share a common biochemical
ilieu, but the hemodynamic effects of LVADs are different
n the two chambers (17). Accordingly, we took advantage
f this difference to test the hypothesis that reverse remod-
ling of the beta-adrenergic pathway is independent of
emodynamic factors and primarily depends on systemic
actors shared by the two ventricles.
ETHODS
eart harvest and pressure-volume relationships. Data
resented in this study were derived from 95 human hearts
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March 1, 2005:668–76 LVADs Improve LV and RV Beta-Adrenergic Responsivenessf patients with end-stage heart failure after orthotopic
eart transplant between October 1999 and July 2003 under
protocol approved by the Institutional Review Board of
he New York Presbyterian Hospital. A total of 65 of the
earts were from medically managed patients undergoing
ransplantation without the need for LVAD support (med-
cal support group), and the other 30 hearts were from
atients requiring LVAD support (HeartMate, Thoratec
o., Pleasanton, California) for more than 30 days before
ransplant. Furthermore, five hearts from nonfailing donors
ot suitable for transplantation were available.
At the time of transplantation, hearts were preserved with
old (4°C) hypocalcemic, hyperkalemic cardioplegia solu-
ion at explant. The passive ventricular pressure-volume
elationships were measured by placing compliant balloons
n the RV and LV as detailed previously (1,9). Right and left
entricular chamber sizes were indexed by the volume
ielding an intraventricular pressure of 30 mm Hg (LVV30
nd RVV30, respectively).
yocardial force generation in response to beta-
drenergic stimulation. Baseline force generation and
orce generation in response to beta-adrenergic stimulation
ere measured from trabeculae (0.8 mm2 cross-sectional
rea) isolated from RVs and LVs in a subset of patients as
escribed previously (9,17). Trabeculae were mounted in a
ath with one end connected to a force transducer and the
ther to a micrometer. Two identical baths (one for the LV
trip and one for the RV strip) were simultaneously perfused
rom the same warming flask containing oxygenated Krebs-
inger solution (37°C; flow rate 1 cc/min; bath volume 1
c). Trabeculae were equilibrated at slack length for 1 h at a
timulation rate of 1 Hz. Trabeculae were then stretched to
max, the length of maximal force generation, and reequili-
rated for 30 min. Adequate muscle oxygenation was
onfirmed as detailed previously (17). After recording base-
ine force, contractile response to beta-adrenergic stimula-
ion was measured by switching to a perfusate of identical
omposition, oxygenation, and temperature containing iso-
roterenol (1 g/ml).
eta-adrenergic receptor density. Beta-antagonist bind-
ng studies were performed to determine beta-receptor
ensity in RV and LV myocardium. All experiments were
one in duplicate in the presence of 100 mM Tris, 5 mM
g Cl2, 1 mM EDTA, pH 7.2; 25 l [
3H]dihydroalpre-
olol ([3H]DHA) 1 to 40 nM, 25 l propranolol (10 M),
r buffer, and 200 g of membrane protein were used for
Abbreviations and Acronyms
LV  left ventricle/ventricular
LVAD  left ventricular assist device
PKA  protein kinase A
RV  right ventricle/ventricular
RyR  ryanodine receptor
SERCA2a  sarcoplasmic reticulum Ca2-ATPase, isoform 2aach assay. Samples were incubated at 37°C for 30 min, and the binding reaction was terminated by rapid filtration on
hatman GF/C filters (Whatman Chemical Separation,
lifton, New Jersey). The filters were dried and counted in
.0 ml of scintillation fluid (ScintiSafe 30%, Fisher Scien-
ific, Pittsburgh, Pennsylvania) for 5 min.
mmunoprecipitation and back-phosphorylation of ryan-
dine receptor (RyR). To test RyR2 protein kinase A
PKA) phosphorylation, RV and LV myocardial homoge-
ates were prepared as detailed previously (10) by homog-
nizing approximately 1.0 g of cardiac tissue in 1.0 ml of a
uffer containing 50 mM Tris-HCl (pH 7.4), 200 mM
aCl, 20 mM NaF, 1.0 mM Na3VO4, 1.0 mM DTT, and
rotease inhibitors. Samples were centrifuged (3,000 g for
0 min), and RyR2 was immunoprecipitated by incubating
00 g of homogenate with anti-RyR antibody in 0.5 ml of
modified RIPA buffer (50 mM Tris-HCL [pH 7.4],
.9% NaCl, 1.0 mM NaF, 1.0 mM Na3VO4, 0.25% Triton
100, and protease inhibitors) overnight at 4°C. Protein A
epharose beads were added, incubated at 4°C for 1 h,
ashed with 1 phosphorylation buffer (8 mM MgCl2, 10
M EGTA, and 50 mM Tris/piperazine-N,N’-bis[2-
thanesulfonic acid], pH 6.8), and resuspended in 10 l of
1.5  phosphorylation buffer containing either PKA
atalytic subunit (Sigma, St. Louis, Missouri) or PKA plus
PKA inhibitor (PKI5–24, 500 nM, Calbiochem, San
iego, California). Back phosphorylation of immunopre-
ipitated RyR2 was initiated with 33 M Mg-ATP con-
aining 10% [-32P]ATP (NEN Life Sciences, Boston,
assachusetts) and terminated after 5 min at room tem-
erature with 5 l of stop solution (4% SDS and 0.25 M
TT). Samples were heated to 95°C, size fractionated on
% SDS-PAGE, and RyR2 radioactivity was quantified
sing a Molecular Dynamics Phosphorimager and Image-
uant software (Ammersham Pharmacia Biotech, Piscat-
way, New Jersey). Nonspecific phosphorylation (not inhib-
ted by PKA inhibitor) was subtracted, the resulting value
as divided by the amount of RyR2 protein (determined by
mmunoblotting and densitometry), and expressed as the
nverse of the PKA-dependent [-32P] ATP signal.
tatistics. Data are expressed as mean  SD values.
ne-way analysis of variance with Bonferroni correction
as used to select differences between groups. The statistical
nalysis was conducted with a commercially available statis-
ical software (SPSS 11.5, Chicago, Illinois). A value of p
.05 was considered to be statistically significant.
ESULTS
atient population. Patient demographics are summarized
n Table 1. Patients requiring LVAD support tended to be
ounger and were mostly male. The distribution between
schemic and idiopathic dilated cardiomyopathic patients
as similar in both groups. All but four of the LVAD
atients were receiving intravenous inotropic support with
obutamine or milrinone before LVAD insertion, while
hese drugs were used in only 49% of transplant patients
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LVADs Improve LV and RV Beta-Adrenergic Responsiveness March 1, 2005:668–76p  0.01). Ten patients received intraaortic balloon pump-
ng before LVAD insertion. The mean duration of the
VAD support was 89.7  72.2 days (range 30 to 360
ays). Inotropic support was discontinued in all LVAD
atients, except one, within one week of LVAD insertion.
Hemodynamic data were collected under anesthesia at
he time of LVAD insertion and at the time of heart
ransplantation for both groups (Table 1). Hemodynamic
arameters at LVAD insertion showed significant elevated
entral venous pressure (p  0.05) and pulmonary artery
iastolic and mean pressures (p  0.001) versus the medi-
ally supported group. Data for the LVAD patients at time
f transplantation were obtained with the device active and
n “auto” mode; LVAD support decreased pulmonary dia-
tolic and mean pressures and improved arterial blood
ressure and cardiac output (p  0.01) significantly versus
he medically supported group.
V and RV size. Ventricular size, indexed by V30, is
ummarized in Figure 1. The mean LVV30 of hearts from
edically supported patients was significantly larger than
hat of hearts after LVAD support (p  0.05) and trended
Table 1. Patient Demographics and Hemodyn
Medica
at Tra
Number of patients 6
Age (yrs) 53.6 
Male/female 42
ICM/DCM 29
CVP (mm Hg) 9.8 
dPAP (mm Hg) 20.5 
mPAP (mm Hg) 27.8 
mAP (mm Hg) 80.1 
CO (l/min) 3.6 
Receiving inotropic support 32 (4
IABP use
Duration of LVAD support (days) N
*p  0.001 vs. LVAD; †p  0.05; ‡p  0.01; §p  0.001 vs
vs. medical support at transplant; **p  0.01; ††p  0.001
CO  cardiac output; CVP  central venous pressure;
pulmonary artery pressure; IABP intraaortic balloon pump
device; mAP  mean arterial pressure; mPAP  mean pulm
igure 1. V30, the ex vivo volume providing a ventricular pressure of 30
m Hg, is an index of ventricular size. Left ventricular (LV) V30 was
ecreased after left ventricular assist device (LVAD) support, but right
entricular (RV) V30 did not change significantly. Ruled bars nonfailing(
earts; black bars  medical support; open bars  LVAD support. All
ata are mean  SD. *p  0.05 vs. LVAD support and nonfailing hearts.oward levels from nonfailing hearts. In contrast, there was
o change between the LVAD and MED group with
espect to RVV30.
yocardial force generation in response to beta-
drenergic stimulation. The cross-sectional area of LV
nd RV endocardial trabeculae were similar between non-
ailing, medical-supported, and LVAD-supported hearts
LV, 0.49  0.13, 0.46  0.14, and 0.45  0.19 mm2,
espectively; RV, 0.42 0.19, 0.41 0.23, and 0.43 0.07
m2, respectively). The myocardial responses to beta-
drenergic stimulation of individual LVAD-supported,
edically supported, and nonfailing hearts are shown in
igure 2. These tracings show that, while the response to
soproterenol is significantly blunted in myocardium of the
edically supported hearts, it is robust and similar to that
bserved in the nonfailing myocardium in both right and
eft ventricular myocardium of LVAD-supported hearts.
aseline and isoproterenol-stimulated force generation,
ummarized in Figures 3A and 3B for all muscles studied
onfirm that, as in the examples of Figure 2, LVAD support
as associated with improved beta-adrenergic responsive-
ess in both LV and RV myocardium. Baseline developed
orce production was similar in LV (MED, 10.25  0.85
N/mm2; LVAD, 9.79  1.41 mN/mm2; nonfailing, 9.53
1.31 mN/mm2) and RV (MED, 13.92 1.56 mN/mm2;
VAD, 23.44  4.1 mN/mm2; nonfailing, 22.48  4.3
N/mm2). However, the increase in force generation in
esponse to isoproterenol was substantially larger in LVAD-
upported patients than in medically supported patients for
uscles from both the LV and RV (Fig. 3C, Table 2). In
ddition, while the maximum rate of force increase (dF/
t) and the maximum rate of force decline (dF/dt) were
imilar at baseline in all groups in LV (dF/dt: nonfailing,
9.4  13.9; MED, 72.5  6.2; LVAD, 69.0  7.2
N/mm2·s and dF/dt: nonfailing, 40.9  6.9; MED,
50.7  4.4; LVAD, 51.9  8.9 mN/mm2·s) and RV
s (Mean  SD)
port
nt
LVAD Support
At Insertion At Transplant
30
48.4  14.1
26/4
13/17
13.4  5.6 10.7  5.4
27.1  6.4¶ 13.8  7.4**
37.4  9.4¶ 19.2  7.5††
† 76.5  8.6 86.6  9.8**
4.1  1.3 5.5  1.6**
26 (87%)# 1 (3%)††
10¶ 0††
NA 89.7  72.2
D support at transplant; p  0.05; ¶p  0.001; #p  0.01
AD support at insertion.
 idiopathic dilated cardiomyopathy; dPAP  diastolic
 ischemic cardiomyopathy; LVAD left ventricular assist
artery pressure; NA  not applicable.amic
l Sup
nspla
5
11.4
/23*
/36
6.4
6.5†
9.2‡
11.9
1.1§
9%)§
0
A
. LVA
vs. LV
DCMdF/dt: nonfailing, 117.5  6.6; MED, 99.4  10.2;
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110.1  1.4; MED, 73.7  8.2; LVAD, 107.3 
1.7 mN/mm2·s) trabeculae, LVAD support lead to a
ignificant improvement during isoproterenol stimulation
Table 2).
Inotropic therapy, commonly used before transplant and
VAD insertion, is known to modify beta-adrenergic re-
ponsiveness. We, therefore, compared responses in patients
eceiving and not receiving such treatment. For medically
reated patients, the increase in myocardial contractile force
n trabeculae from patients receiving intravenous inotropic
gents before transplant (mean increase in isometric devel-
ped force generation of 6.40  1.37 mN/mm2 for LV and
.16  2.38 mN/mm2 for RV) was no different than that in
yocardium from patients treated without inotropic agents
mean increase in isometric developed force generation of
.82  1.18 mN/mm2 for LV and 10.86  1.5 mN/mm2
or RV). Only one of the LVAD patients was receiving
notropic support before transplant.
It is also known that chronic beta-blocker treatment can
mprove inotropic response to beta-adrenergic stimulation.
en of the medically treated patients for whom muscle data
re available were receiving beta-blockers up to the time of
ransplant. In these patients the mean increase of developed
orce in response to isoproterenol was 9.18  0.72 mN/
m2 (n  10), which compared with 6.6  1.22 mN/mm2
or patients who never received a beta-blocker (n  19, p 
.05). Thus, beta-blocker treatment can improve beta-
drenergic responsiveness but to a much lesser degree than
igure 2. Representative force tracing from right ventricular (RV) and left
1 g/ml). Whereas responses were blunted in RV and LV muscle of medi
arkedly improved responses in both ventricles similar to nonfailing h
soproterenol. Scale bar  30 s.o LVADs. For RV trabeculae the mean increase in seveloped force generation in response to isoproterenol was
1.35  2.86 mN/mm2 in patients receiving beta-blocker
herapy (n  5) and 9.59  2.25 mN/mm2 in patients not
eceiving beta-blocker treatment (n  11), but this differ-
nce did not reach significance. There was not sufficient
ata to make this assessment for the LV or RV trabecular
ata of LVAD patients, because only two were taking
eta-blockers at the time of transplant.
Finally, the duration of LVAD support did not correlate
ith the magnitude of force response to isoproterenol in this
roup. Note, however, that LVAD patients supported for
30 days were excluded from study.
eta-adrenergic receptor density. Scatchard analysis of
3H]DHA binding demonstrated a significant difference in
eta-adrenergic receptor density in the medically supported
roup compared with the LVAD-supported and nonfailing
roup in both the LV and RV. Representative Scatchard
lots of LV and RV myocardial samples for all groups are
hown in Figures 4A and 4B. Averaged values for the
eceptor density (indexed by the plateau of the binding
urve, Bmax) are presented in Figure 4C and Table 3. In
earts receiving LVAD treatment before transplant, Bmax
as significantly increased in both LV and RV in compar-
son with medically supported hearts (p 0.01) and reached
lmost normal levels. No significant differences existed
n the receptor affinity (Kd) in any of the tissue studied
Table 3).
Although beta-agonist therapy can, in general, influence
eta-receptor density, this was not the case in these end-
icular (LV) endocardial trabeculae showing the responses to isoproterenol
anaged transplanted hearts, left ventricular assist device (LVAD) support
Arrows  time when perfusion was switched to solution containingventr
cally mtage heart failure patients, a finding that is concordant with
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ile force noted above. Among patients not receiving beta-
lockers, beta-receptor density averaged 24.9  4.3
mol/mg and 30.5  3.5 fmol/mg for the LV and RV,
espectively, in patients not receiving beta-agonist therapy
efore transplant, compared with 23.2  1.1 fmol/mg and
5.6  0.6 fmol/mg, respectively, in those receiving beta-
gonist therapy.
VAD treatment reverses RV and LV PKA hyperphos-
horylation of cardiac RyR2. Ryanodine receptor was
mmunoprecipitated (IP) from RV and LV samples of
igure 3. Change of developed (filled lines) and diastolic (dashed lines) is
rabeculae from baseline to peak response to isoproterenol perfusion (1 
ncreased developed isometric force generation in both the LV and RV m
erfusion. Ruled bars  nonfailing hearts; black bars  medical support;
s. medical support.
able 2. Mechanical Parameters of Isolated Trabeculae at
soproterenol Stimulation
dF/dt,
mN/mm2·s
dF/dt,
mN/mm2·s
V
NF 260.3  40.0 220.8  34.5
MED 150.8  12.2* 114.8  9.2*
LVAD 317.4  71.3 281.4  62.5
V
NF 603.5  75.1 407.0  53.5
MED 291.1  45.0† 232.3  35.4
LVAD 474.9  63.4 355.7  49.8‡
p  0.01 and †p  0.05 vs. NF and LVAD; ‡p  0.05 vs. MED.
LV  left ventricular; LVAD  left ventricular assist device support; MED s
edical support; NF  nonfailing; RV  right ventricular; dF/dt  maximum rate
f force increase; dF/dt  maximum rate of force decline.ormal (n  3), medically managed (n  2), and LVAD-
upported (n  4) hearts and were back-phosphorylated
ith [-32P]ATP in the presence of PKA (Fig. 5A); the
ncreased signal (darker band) corresponds to higher
mounts of 32P transferred to RyR2 by PKA, which is
ndicative of reduced RyR2 PKA phosphorylation in vivo. A
imilar reaction carried out in the presence of PKA inhibitor
PKI) was performed to quantify background levels of
onspecific 32P incorporation. As shown in representative
xamples (Fig. 5A), the RyR2 32P signals after treatment
ith PKA were significantly higher in samples from normal
nd LVAD samples than from medically managed patients,
ndicating that the in vivo PKA phosphorylation of RyR2
as significantly reduced by LVAD treatment as previously
eported (11). Moreover, the LVAD-associated reduction
n RyR2 PKA hyperphosphorylation was similar in LV and
V (Fig. 5B).
ISCUSSION
onsistent with our prior study (17), LVAD support
ormalized systemic hemodynamics, markedly reduced he-
odynamic load on the LV, but did not significantly change
he preload on the RV. Thus, hemodynamic changes were
ssociated with reverse structural remodeling of the LV, but
ot the RV. Despite these differential hemodynamic and
ic force of left ventricle (LV) (A) and right ventricle (RV) (B) endocardial
). Left ventricular assist device (LVAD) support resulted in significantly
. (C) Change in isometric developed force generation after isoproterenol
bars  LVAD support. All data are mean  SEM. *p  0.01, †p  0.05ometr
g/ml
uscle
opentructural remodeling effects of LVAD support, we observed
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March 1, 2005:668–76 LVADs Improve LV and RV Beta-Adrenergic Responsivenessqual recovery of beta-adrenergic myocardial responsive-
ess, beta-adrenergic receptor density, and reversal of RyR2
yperphosphorylation in the RV and LV. This suggests that
everse remodeling of the beta-adrenergic pathway during
VAD support is primarily mediated by systemic factors
such as biochemical milieu) and is not directly mediated by
emodynamic factors.
We have previously shown through a comparison of
V and RV properties of LVAD-supported hearts that
emodynamic unloading, not neurohormonal factors, is
rimarily responsible for decreasing myocyte diameter,
ecreasing ventricular chamber size, increasing relative
ollagen content, increasing SERCA2a expression, and
mproving the myocardial force-frequency relationship
17). We hypothesized, however, that this may not
ecessarily be the case for other aspects of reverse
emodeling. Given the strong dependence of regulation
igure 4. Representative Scatchard blots of [3H]DHA binding in left vent
triangles), medical (squares), and left ventricular assist device (LVAD)-su
yocardial samples of nonfailing (ruled bars), medical (black bars), and
aximal binding (Bmax) values determined from Scatchard transformation o
Table 3. Bmax and Kd Values for [
3H]DHA B
RV of Nonfailing, Medical, and LVAD-Suppo
Nonfailing
LV RV
Bmax (fmol/mg) 50.0  2.8 48.0  4.2 24
Kd (nM) 18.0  0.4 17.6  0.38 13
Values are means  SD for maximal binding (Bmax) and rec
of saturation binding data. *p  0.01 compared with nonfailing an
LV  left ventricle; RV  right ventricle.f beta-adrenergic signaling on circulating catecholamine
evels and recent evidence showing that LVAD support
ormalizes neurohormonal milieu (11,26) (including cir-
ulating norepinephrine levels), restores beta-adrenergic
eceptor density, and improves the ability of cardiac
uscle to respond to beta-adrenergic stimulation (13),
e hypothesized that functional restoration of this path-
ay would be mediated by systemic factors, a hypothesis
hat is confirmed by the present results.
Importantly, because structural and other key aspects of
everse remodeling identified in the present and our prior
tudy (17) occur only in the LV, the results of the present
tudy indicate that restoration of beta-adrenergic pathway
unction is not sufficient to reverse all of the abnormalities of
nd-stage failing hearts requiring transplantation.
We have previously shown that the calcium release
hannel of the sarcoplasmic reticulum (SR) is PKA hyper-
r (LV) (A) and right ventricular (RV) (B) samples are shown of nonfailing
ed hearts (circles). (C) Density of beta-adrenergic receptors in LV and RV
D-supported hearts (open bars). Data reported are the means  SD of
rated binding data. *p 0.01 vs. nonfailing and LVAD-supported hearts.
g to Beta-Adrenergic Receptors in LV and
Hearts
edical Support LVAD Support
RV LV RV
1.9* 29.0  3.4* 39.2  2.5 39.8  1.7
0.5 15.2  1.52 16.5  0.38 16.9  0.69
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inase A hyperphosphorylation causes defective RyR2 func-
ion (including increased channel open probability due to
ncreased calcium-dependent activation). The defective
yR2 function results in “leaky” channels that can deplete
R calcium stores and contribute to reduced calcium tran-
ients that likely contribute to impaired contractility in
ailing hearts. We have recently shown that these abnor-
alities are reversed in the LV by LVAD support (10). We
ave also recently demonstrated that RyR2 structure and
unction can be normalized by beta-blocker administration
n dogs with pacing-induced heart failure (24). The hyper-
drenergic state of heart failure may underlie the defects in
yR2 structure (depletion of FK506 binding protein 12.6
nd reduced phosphatase levels in the RyR2 macromolecu-
ar complex) and function (increased open probability and
ncreased calcium-dependent activation) (10). The normal-
zation of RyR2 structure and function by LVADs and
eta-blockers may be explained by the fact that both
herapies effectively reverse the hyperadrenergic state of
eart failure; LVADs, by reducing circulating catechol-
mine levels, and beta-blockers, by blocking the cellular
ctions of circulating catecholamines. These observations
re complimentary in pointing toward primary biochemical
echanisms as being responsible for improved RyR2 struc-
ure and function, independent of hemodynamic factors.
igure 5. (A) Ryanodine receptor 2 (RyR2) immunoblots (lower panel) and
mounts of 32P transferred to RyR2 by protein kinase A (PKA), which is
resent in right ventricle (RV) RyR2 immunoblot. There is no special signi
hat the samples from nonfailing, medically, and left ventricular assist dev
ottom bands) indicates that these samples are comparable and that measu
he two bands. Moreover, this does not represent nonspecific degradation as
n failing myocardium, but was normalized by LVAD support in both ventr
F  heart failure; PKI  protein kinase A inhibitor.One factor, which has complicated interpretation of data telated to reverse remodeling from studies involving hearts
f LVAD and transplant patients, has been differences in
edical regimen within and between groups. Most LVAD
atients receive inotropic treatment before LVAD insertion,
ut this is usually withdrawn within about a week of surgery.
dditionally, many medically supported patients now re-
eive beta-blocker treatment before transplant. Prior studies
ave shown that especially metoprolol therapy is able to
aintain or upregulate beta-receptor density, while conflict-
ng data regarding carvedilol have been published with some
tudies suggesting downregulation of beta-receptor density
27,28) and another study showing an upregulation (25).
owever, myocardial force generation in isolated right atrial
rabeculae in response to maximum stimulation with iso-
roterenol was no different (29). In the present study, we
id not see that preoperative beta-agonist treatment signif-
cantly influenced beta-receptor density or overall beta-
drenergic myocardial contractile responsiveness in the
edically treated end-stage heart failure patients (change in
eveloped force generation in response to isoproterenol with
arvedilol was 8.31  0.60 mN/mm2 in comparison with
etoprolol with 9.96  1.90 mN/mm2; p  NS). In
ddition, although pretransplant utilization of beta-blockers
id upregulate beta-receptor density, the magnitude of this
ffect was far less than observed in the LVAD group. Thus,
ystematic changes in medical treatments do not influence
phosphorylation gels. For the latter, the darker bands correspond to higher
ative of reduced RyR2 PKA phosphorylation in vivo. Note double band
e to the double bands in the RyR2 samples from the RV—moreover, given
VAD)-supported hearts are all equivalent (equal densities of the top and
nts of the PKA phosphorylation levels are not affected by the presence of
would result in a smear. (B) RyR2 phosphorylation was markedly increased
*p 0.01 vs. nonfailing and LVAD-supported hearts. LV left ventricle;back
indic
ficanc
ice (L
reme
that
icles.he major conclusions of this study.
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March 1, 2005:668–76 LVADs Improve LV and RV Beta-Adrenergic ResponsivenessBy design, LVAD patients supported for 30 days were
xcluded from this study. We have previously shown that 30
ays of support is sufficient for molecular remodeling and
or a majority of structural characteristics of reverse remod-
ling to reach near maximal values (12). It was, therefore,
nticipated that we would not see any association between
uration of LVAD support and recovery of beta-adrenergic
yocardial responsiveness.
tudy limitations. Left ventricular assist devices have been
hown in the past to normalize neurohormone and other
ytokine levels (2,7,11,26). We did not measure these
actors in our group of patients. However, in prior studies
he degree of normalization of these factors has been
rofound and uniform (i.e., every neurohormone examined
hus far that is abnormally elevated in heart failure is
ormalized by LVAD support). Therefore, even had they
een measured, it would not have been possible to mecha-
istically link recovery of the beta-adrenergic pathway to
ormalization of a particular neurohormone or cytokine. In
ddition, we assessed the myocardial force response of
solated trabeculae to beta-adrenergic stimulation with iso-
roterenol only to the maximum dose and did not perform
dose-response relationship. Only a small amount of
yocardial tissue was available for measuring beta-receptor
ensity and RyR2 phosphorylation, so the statistical power
s low, and these results should be seen with caution. In
ddition, we did not find any upregulation in beta-receptor
ensity in patients receiving beta-agonist therapy before
ransplantation. However, it is known that beta-blocker
herapy is able to maintain or upregulate beta-receptor
ensity (27–29). Because of the low samples size, a differ-
ntiation of beta-blocker therapy in effectiveness of beta-
eceptor density was not possible. Finally, availability of
ormal human tissue is becoming increasingly limited in our
nstitution, and RV functional data from only two nonfail-
ng hearts were available for this study. Over the past 5 years
ince our studies began, we have obtained only five normal
earts and none in the last 12 months. Therefore, the
resent study primarily shows improvements in RV myo-
ardial properties during LVAD support compared with
edically supported hearts, but does not definitively show
hat LVADs truly normalize RV myocardial properties in
omparison with LV properties.
onclusions. When used to bridge critically ill patients to
ransplant, LVAD support has been associated with im-
roved ventricular function to the point where LVADs have
een explanted without transplantation (30–32). Although
his recovery does not appear to be uniform and may not be
ermanent in most patients undergoing LVAD explanta-
ion (30–34), an understanding of the mechanisms under-
ying the unprecedented degree and scope of reverse remod-
ling could lead to development of less invasive means of
chieving the same goal. Prior studies have indicated the
rime importance of hemodynamic factors in mediating
any aspects of reverse remodeling. The results of theresent study provide new and important insight intoechanisms of reverse remodeling by showing that systemic
actors (e.g., biochemical milieu) are important for normal-
zing the myocardial beta-adrenergic axis.
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